All News

handcropped.RA_.jpg

Tapering Of Therapy In RA: Maybe Not So Aggressive Next Time

d Philip Robinson, MBChB, PhD, FRACP

This ACR has seen some more great work on tapering of therapy in rheumatoid arthritis. It’s a hot topic and one which I get asked about all the time by my patients.

Read Article
vaccine.jpg

Herpes Zoster Vaccine Update

d Cassandra Calabrese, DO

Shingrix (GSK), the herpes zoster subunit vaccine (a two-shot series), was approved by the FDA in Fall 2018 and is currently approved for use in adults 50 years and older.

Read Article
podcastLogo-01%20RESIZED.jpg

RheumNow Podcast –Favorites of ACR 2019 (11.22.19)

d Jack Cush, MD

Dr. Jack Cush recaps standout presentations and information from ACR 2019 held in Atlanta November 9-12, 2019.

Read Article
woman-1284353_640.jpg

A Focus on WOCBA (Women of Childbearing Age)

d Maeve Gamble, MD

Largely because it can be difficult to do studies in pregnant women, gaps remain in the area of rheumatic disease in pregnancy. This year’s ACR highlights some important new points to consider.

Read Article
Convention2.jpg

ACR 2019 - Report From Day 3 (Tuesday)

d Jack Cush, MD

Here's my summary of key studies presented Tuesday. 



Tofacitinib in Polyarticular JIA

Read Article
ACRmtg.jpg (keep)

Psoriatic Arthritis at ACR 2019

d Jack Cush, MD

Below are several of the highlight studies in psoriatic arthritis (PsA) presented at the ACR 2019 annual meeting in Atlanta. 

Read Article
dumbbells-2465478_640.jpg

Muscle Loss and Frailty in Rheumatic Disease

d Paul Sufka, MD

At the 2019 ACR annual meeting, several abstracts looked at the importance of myopia (muscle wasting due to illness at any age) and sarcopenia (age related muscle wasting) in the setting of various rheumatologic diseases.

Read Article
acr_session2.jpeg

ACR 2019 - Report From Day 2 (Monday)

d Jack Cush, MD

Monday was another full day of sessions and studies here in Atlanta. Following is my roundup of day two.

The Safety of Methotrexate

Read Article
The RheumNow Podcast is up! Favorite abstracts from ACR 2019. View it here>> https://t.co/LKCC0y4fCr or listen to the podcast >> https://t.co/bsiY1HI9Dn

Links:

Dr. John Cush RheumNow ( View Tweet)

Pre-existing autoimmune disease is NOT a contraindication to checkpoint inhibitor therapy. 29% flare rate, mostly mild and manageable Abstracts#253 #ACR19 @CCalabreseDO

Dr. John Cush RheumNow ( View Tweet)

One of the hardest things about PMR is getting a reliable diagnosis - no biomarker and no histopath. Imaging has potential, and my colleague @drceowen has made a simple algorithm for reliable/replicable PET/CT dx 👍 #ACR19 ABST0755 @drdavidliew https://t.co/XC5iLO2uE9 https://t.co/DHHW2bMMvm

Links:

Dr. John Cush RheumNow ( View Tweet)
VERVE results - Live zoster vaccine safe and effective in >600 patients with autoimmune diseases treated wth TNFi abstr#0824 #ACR19 @CCalabreseDO https://t.co/F8ipuG08O3

Links:

Dr. John Cush RheumNow ( View Tweet)

It's Dr. Paul Sufka @psufka talking about methotrexate and prednisone for Hand osteoarthritis https://t.co/fnvIs3LnYs #ACR19 @philipcrobinson

Links:

Dr. John Cush RheumNow ( View Tweet)

The draft 2020 ACR #gout guidelines were presented at the last slot of the meeting. Big changes for ULT initiation #ACR19 @philipcrobinson [Slides attached] https://t.co/4g3YUlm7Sa

Links:

Dr. John Cush RheumNow ( View Tweet)

Long term results for GCA pts on TCZ (GiACTA): No new safety signals. Nearly 50% of those on TCZ QW maintained remission. Flares noted in PBO/ cessation TCZ and remission restored in majority once TCZ restarted. https://t.co/DN6TWYgWsH Plenary abs #808 #ACR19 @uptoTate

Links:

Dr. John Cush RheumNow ( View Tweet)

99mTc-maraciclatide (which binds integrins) whole body imaging has similar uptake to PDUS evaluation for synovial inflammation. It is quick, and widely available. Cost may be prohibitive, however. Abstract #286 https://t.co/4LqrzcoA9U #ACR19 @uptoTate

Links:

Dr. John Cush RheumNow ( View Tweet)

ACR has released 3 FREE "SPOTLIGHT" Slide Decks on RA, SLE, SpA; ~15 slides each deck; compilations of cool abstracts presented at #ACR19. Use the link supplied below https://t.co/CsKVMDoGoL

Links:

Dr. John Cush RheumNow ( View Tweet)

FINCH3: FILGOTINIB studied in this cohort naive to MTX; interesting that safety data looks good! Maybe too early to tell. Abst# 927 https://t.co/AonswiGYG3 https://t.co/q3OU582WbT

Links:

Dr. John Cush RheumNow ( View Tweet)
abstr#0848 - Retrospective study Medicare database to evaluat outcomes of chronic low dose steroids (GCs) in Rheum Dz: n= 246,297, 47% on GCs. Pts on steroids have : 1. ⬆️ use of narcotics (pain) 2. RA 3. ⬆️hosp visits related to infx 4. Less f/u https://t.co/xD8isyKZsz

Links:

Dr. John Cush RheumNow ( View Tweet)

Plenary session shows AA/blacks at higher risk for #SLE & that blacks have 16 fold increased risk for IHD, CVD. CV risk accelerated at yrs 1 & 10. Copy & paste. #ACR19 Abst 805 https://t.co/pW8JdGxCUf https://t.co/lLPTnyTa2z

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×